These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 31046703)
21. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. Moxley RT; Pandya S; Ciafaloni E; Fox DJ; Campbell K J Child Neurol; 2010 Sep; 25(9):1116-29. PubMed ID: 20581335 [TBL] [Abstract][Full Text] [Related]
22. The effect of steroid treatment on weight in nonambulatory males with Duchenne muscular dystrophy. Lamb MM; Cai B; Royer J; Pandya S; Soim A; Valdez R; DiGuiseppi C; James K; Whitehead N; Peay H; Venkatesh SY; Matthews D; Am J Med Genet A; 2018 Nov; 176(11):2350-2358. PubMed ID: 30256515 [TBL] [Abstract][Full Text] [Related]
23. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ; Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897 [TBL] [Abstract][Full Text] [Related]
24. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Wein N; Alfano L; Flanigan KM Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172 [TBL] [Abstract][Full Text] [Related]
25. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials. Schreiber A; Brochard S; Rippert P; Fontaine-Carbonnel S; Payan C; Poirot I; Hamroun D; Vuillerot C; Dev Med Child Neurol; 2018 Feb; 60(2):185-191. PubMed ID: 28990163 [TBL] [Abstract][Full Text] [Related]
26. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H; Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484 [TBL] [Abstract][Full Text] [Related]
27. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. McAdam LC; Mayo AL; Alman BA; Biggar WD Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512 [TBL] [Abstract][Full Text] [Related]
28. Fracture in Duchenne Muscular Dystrophy: Natural History and Vitamin D Deficiency. Perera N; Sampaio H; Woodhead H; Farrar M J Child Neurol; 2016 Aug; 31(9):1181-7. PubMed ID: 27221372 [TBL] [Abstract][Full Text] [Related]
29. Risk Factors for First Fractures Among Males With Duchenne or Becker Muscular Dystrophy. James KA; Cunniff C; Apkon SD; Mathews K; Lu Z; Holtzer C; Pandya S; Ciafaloni E; Miller L J Pediatr Orthop; 2015 Sep; 35(6):640-4. PubMed ID: 25379822 [TBL] [Abstract][Full Text] [Related]
31. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Gloss D; Moxley RT; Ashwal S; Oskoui M Neurology; 2016 Feb; 86(5):465-72. PubMed ID: 26833937 [TBL] [Abstract][Full Text] [Related]
32. What can Duchenne Connect teach us about treating Duchenne muscular dystrophy? Wang RT; Nelson SF Curr Opin Neurol; 2015 Oct; 28(5):535-41. PubMed ID: 26356412 [TBL] [Abstract][Full Text] [Related]
33. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan. Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384 [TBL] [Abstract][Full Text] [Related]
34. Corticosteroid therapy for duchenne muscular dystrophy: improvement of psychomotor function. Sato Y; Yamauchi A; Urano M; Kondo E; Saito K Pediatr Neurol; 2014 Jan; 50(1):31-7. PubMed ID: 24138948 [TBL] [Abstract][Full Text] [Related]
35. Neurobehavioral Concerns Among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network. Caspers Conway K; Mathews KD; Paramsothy P; Oleszek J; Trout C; Zhang Y; Romitti PA; J Dev Behav Pediatr; 2015; 36(6):455-63. PubMed ID: 26020585 [TBL] [Abstract][Full Text] [Related]
36. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy. Kim S; Zhu Y; Romitti PA; Fox DJ; Sheehan DW; Valdez R; Matthews D; Barber BJ; Neuromuscul Disord; 2017 Aug; 27(8):730-737. PubMed ID: 28645460 [TBL] [Abstract][Full Text] [Related]
37. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648 [TBL] [Abstract][Full Text] [Related]
38. Idiopathic intracranial hypertension in a child with Duchenne muscular dystrophy. Weig SG; Zinn MM; Howard JF Pediatr Neurol; 2011 Dec; 45(6):406-8. PubMed ID: 22115006 [TBL] [Abstract][Full Text] [Related]
40. A population-based study of scoliosis among males diagnosed with a dystrophinopathy identified by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Conway KM; Gedlinske A; Mathews KD; Perlman S; Johnson N; Butterfield R; Hung M; Bounsanga J; Matthews D; Oleszek J; Romitti PA Muscle Nerve; 2022 Feb; 65(2):193-202. PubMed ID: 34787322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]